Advertisement
News
Subscribe to MDT Magazine News

Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation

May 11, 2011 8:34 am | by Bio-Medicine.Org | Comments

NATICK, Mass., May 11, 2011 /- Boston Scientific Corporation (NYSE: BSX ) today announced that a jury in the District Court for the District of Delaware found that Cordis Corporation owed Boston Scientific approximately $19.5 million for infringing its Jang patent, which covers...

TOPICS:

Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society

May 11, 2011 8:33 am | by Bio-Medicine.Org | Comments

SAN DIEGO, May 11, 2011 /- Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society (ATS) in Denver, Colorado.  The poster, titled "The LPA1 Antagonist, AM152,...

TOPICS:

Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix

May 11, 2011 7:39 am | by Bio-Medicine.Org | Comments

FORT WORTH, Texas, May 11, 2011 /- Healthpoint Biotherapeutics today announced the introduction of OASIS® Ultra Tri-Layer Matrix, a natural extracellular matrix (ECM) material derived from three layers of porcine small intestinal submucosa (SIS). The three-layer construct of ECM was...

TOPICS:
Advertisement

Prexa releases details on $7M funding

May 11, 2011 7:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Prexa Pharmaceuticals today revealed that Shire Pharmaceuticals was among the investors in Prexa's $7 million Series B financing, which was first reported in a filing with the U.S. Securities and Exchange Commission in late April.

TOPICS:

Draft Guidance for Industry and Food and Drug Administration Staff - Establishing the Performance Characteristics of In Vitro Diagnostic Devices for Chlamydia trachomatis and/...

May 11, 2011 6:32 am | by U.S. Food & Drug Administration | Comments

These devices are used to aid in the diagnosis of urogenital C. trachomatisand/or N. gonorrhoeae infection. They include devices that detect one specific organism, as well as devices that may detect both organisms with or without further differentiation.

TOPICS:

Summary Information for: Scandinavian Total Ankle Replacement System (STAR Ankle)

May 11, 2011 6:32 am | by U.S. Food & Drug Administration | Comments

Labeling, Approval Order, and Summary of Safety and Effectiveness for Scandinavian Total Ankle Replacement System (STAR Ankle) (P050050).

Seventh Sense Biosystems secures $6.7M funding

May 11, 2011 6:32 am | by Mass High Tech: The Journal of New England Technology | Comments

Seventh Sense Biosystems Inc., a four-year-old medical device company in Cambridge, has raised about $6.7 million in equity financing, with a plan to close the funding at about $12 million, according to federal documents.

Wavemark sweeps up $3M in new debt funding

May 11, 2011 6:32 am | by Mass High Tech: The Journal of New England Technology | Comments

Health-care RFID tech company Wavemark Inc. has taken in $2.8 million of a planned $3 million debt financing round, according to federal documents.

Advertisement

Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate

May 11, 2011 6:31 am | by Bio-Medicine.Org | Comments

LOS ANGELES, May 11, 2011 /- Instacare Corp. (OTCQB: ISCR), the exclusive provider of the Shasta Genstrip, a revolutionary diagnostic product targeted at the $20 billion diabetes care marketplace, a leading provider of prescription diagnostics and home testing products for the chronically...

TOPICS:

Medtronic picks GE's Omar Ishrak as next CEO

May 11, 2011 5:45 am | by The Associated Press | Comments

Medtronic Inc., the world's biggest medical device maker, said Wednesday that Omar Ishrak of GE Healthcare will become its new chairman and CEO in June.Ishrak, 55, will join the company on June 13. He had been the president and CEO of General Electric Co.'s health care systems business, and...

China Pharma Holdings, Inc. Reports First Quarter 2011 Financial Results

May 11, 2011 5:34 am | by Bio-Medicine.Org | Comments

HAIKOU CITY, China, May 11, 2011 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE AMEX: CPHI ) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the quarter ended March 31, 2011. F irst...

TOPICS:

ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor

May 11, 2011 5:34 am | by Bio-Medicine.Org | Comments

EXTON, Pa., May 11, 2011 /- ViroPharma Incorporated (Nasdaq: VPHM ) and Halozyme Therapeutics (Nasdaq: HALO)announced today that Halozyme has granted ViroPharma an exclusive worldwide license to use Halozyme's proprietary Enhanze™ technology, a proprietary drug delivery platform...

TOPICS:

Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor human)

May 11, 2011 5:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, May 11, 2011 /- Halozyme Therapeutics, Inc. (Nasdaq: HALO ) and ViroPharma Incorporated (Nasdaq: VPHM ), today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) in the development of a subcutaneous...

TOPICS:

Medco Research Institute® and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medicat...

May 11, 2011 5:33 am | by Bio-Medicine.Org | Comments

FRANKLIN LAKES, N.J. and CINCINNATI, May 11, 2011 /- Medco Research Institute LLC , a wholly owned subsidiary of Medco Health Solutions Inc. (NYSE: MHS ), and AssureRx Health Inc. today announced the initiation of the PREDICT PSYMEDS pilot [Pharmacogenetic-Directed Prescribing of...

TOPICS:

Quest Diagnostics Announces Completion of Final Extension of the Subsequent Offering Period and Intent to Exercise Top-Up Option and Complete Merger

May 11, 2011 5:33 am | by Bio-Medicine.Org | Comments

MADISON, N.J., May 11, 2011 /- Quest Diagnostics Incorporated (NYSE: DGX ), the world's leading provider of diagnostic testing, information and services, and Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), announced today the completion of the final extension of the...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading